Compound Report Content (8 profiles): Populated full editorial content across all 9 sections (history, pharmacology, safety profile, key trials, clinical outlook, regulatory status, commercial outlook, commercial outlook details, comparative context) for DMT, 5-MeO-DMT, Ibogaine, Ketamine, Mescaline, Salvia Divinorum, Nitrous Oxide, and Placebo. Placebo received substantive methodological treatment covering the history of RCTs in psychedelic research, active placebo strategies (niacin, diphenhydramine, low-dose compound), blinding integrity measurement, landmark trials (MAPS MDMA Phase 3, Imperial escitalopram comparison, COMPASS Phase 2b), and the FDA's 2024 MDMA advisory committee decision and its implications for the field.
Overview Images (23 added): Added compound overview images for 2C-x, 5-MeO-DMT, DMT, Esketamine, LSD, Mescaline, Placebo, and country overview images for Jamaica, Japan, Jordan, Kazakhstan, Lithuania, Malaysia, Mexico, Monaco, Netherlands, New Zealand, Pakistan, Singapore, Slovakia, South Africa, South Korea, Sweden, and Taiwan. Removed outdated the-netherlands.png duplicate.
Welcome Email Sequences: Built complete drip email engine with 7 user segments — free signup welcome (15-min delay), legacy user re-engagement (cohorted 250/day rollout), Pro Individual onboarding, Pro Team onboarding, Pro Enterprise onboarding, team/enterprise member welcome, and subscription renewal reminders (30d, 7d, expiry). Includes declarative sequence definitions, Clerk privateMetadata state tracking, hourly cron processor, and Stripe webhook transitions for free-to-pro upgrades with expiresAt computation.